) --

Ariad Pharmaceuticals



) hit a new 52-week high Friday as it is currently trading at $16.83, above its previous 52-week high of $16.75 with 1.4 million shares traded as of 11:15 a.m. ET. Average volume has been 3.4 million shares over the past 30 days.

Ariad has a market cap of $2.59 billion and is part of the

health care

sector and


industry. Shares are up 34.9% year to date as of the close of trading on Thursday.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Ariad as a


. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full

Ariad Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center